Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, successfully closed its underwritten public offering of 20,010,000 shares of common stock at a price of $5.75 per share. This includes 2,610,000 additional shares issued following the full exercise of the underwriters' option to purchase extra shares. The public offering generated approximately $115.1 million in proceeds before accounting for discounts, commissions, and expenses. Joint book-running managers for the offering were Morgan Stanley, Leerink Partners, Stifel, and Cantor. Trevi is currently developing Haduvio™, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。